Vardakas Konstantinos Z, Theocharis George, Tansarli Giannoula S, Rafailidis Petros, Falagas Matthew E
Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23, Marousi, Athens, Greece.
Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Iaso Group, Athens, Greece.
Arch Virol. 2016 Sep;161(9):2511-8. doi: 10.1007/s00705-016-2941-5. Epub 2016 Jul 1.
To evaluate the factors associated with oseltamivir prescription and to study the effectiveness of oseltamivir in reducing influenza-related complications. A prospective cohort study using the SOS Doctors (a network of physicians who perform house-call visits in Attica, Greece). Patients with confirmed or clinically suspected influenza were followed up to 14 days during the 2011-2012 influenza period. 410 patients with confirmed or suspected influenza were included. Healthy adults were mainly enrolled, with a median age of 44 years. Influenza diagnosis was mainly based on clinical criteria (65.8 % of patients). Oseltamivir was prescribed for 45.4 % of them. In a multivariate analysis, prescription of oseltamivir was associated with the attending physician (p < 0.001), positive influenza test (p < 0.001) and diabetes (p = 0.027). Data on complications were available for 351 patients, and 50 (15.8 %) of them reported at least one. Seven patients required hospitalization. Types of complications (pneumonia, bronchitis, etc.) were not significantly different between patients receiving and those not receiving oseltamivir. In the multivariate analysis, higher oseltamivir prescription rate was associated with fewer complications (p < 0.001). Bearing in mind the limitations of a non-randomized study, in a real-life setting, oseltamivir prescription and the rate of complications in patients with influenza were associated with the attending physician, underlying diseases and diagnostic tests. Overall, when the frequency of oseltamivir prescription increased, the influenza-related complications decreased.
评估与奥司他韦处方相关的因素,并研究奥司他韦在减少流感相关并发症方面的有效性。一项前瞻性队列研究,使用了SOS医生(希腊阿提卡地区提供上门医疗服务的医生网络)。在2011 - 2012年流感季节,对确诊或临床疑似流感的患者进行了长达14天的随访。纳入了410例确诊或疑似流感的患者。主要纳入健康成年人,中位年龄为44岁。流感诊断主要基于临床标准(65.8%的患者)。其中45.4%的患者开具了奥司他韦。在多变量分析中,奥司他韦的处方与主治医生(p < 0.001)、流感检测呈阳性(p < 0.001)和糖尿病(p = 0.027)相关。351例患者有并发症数据,其中50例(15.8%)报告至少有一种并发症。7例患者需要住院治疗。接受奥司他韦和未接受奥司他韦的患者之间并发症类型(肺炎、支气管炎等)无显著差异。在多变量分析中,奥司他韦处方率较高与并发症较少相关(p < 0.001)。考虑到非随机研究的局限性,在现实生活中,流感患者的奥司他韦处方和并发症发生率与主治医生、基础疾病及诊断检查有关。总体而言,当奥司他韦处方频率增加时,流感相关并发症减少。